Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Viking Therapeutics Unusual Options Activity For September 24
Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.
Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.
10 Health Care Stocks With Whale Alerts In Today's Session
Skye Stock Rallies 22% Following Weight-loss Drug Update